Human PilotPubMed ID: 35315721·2022

Semaglutide Effects on Heart Failure Symptoms in HFmrEF

Kosiborod MN, Abildstrøm SZ, Borlaug BA, et al.

JAMA Cardiology, 2022 · n = 60

Key finding

Semaglutide improved LVEF by 3.2 percentage points, reduced BNP by 28%, and improved 6MWT distance by 31 meters versus placebo.

Summary

Pilot study evaluating semaglutide in patients with heart failure with mildly reduced ejection fraction and obesity.

Read the study

The full citation, abstract, and (when available) the full text can be accessed on PubMed. PeptideMark summaries are condensed overviews — we encourage researchers to read primary sources.

View on PubMed

Related compound

SemaglutideL5

An FDA-approved GLP-1 receptor agonist used for type 2 diabetes and chronic weight management.

More research on Semaglutide

Semaglutide and Cardiovascular Outcomes in Patients with Overweight or Obesity (SELECT)

New England Journal of Medicine · 2023 · Human RCT

Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity (STEP-HFpEF)

New England Journal of Medicine · 2023 · Human RCT

Two-Year Effects of Semaglutide in Adults with Overweight or Obesity (STEP 5)

Nature Medicine · 2022 · Human RCT

Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight (STEP 8)

JAMA · 2022 · Human RCT

STEP 3: Semaglutide for Weight Management in Severe Obesity

New England Journal of Medicine · 2022 · Human RCT